Status:
COMPLETED
Determination of Prevalence and Features of HRRm mCRPC (ADAM)
Lead Sponsor:
AstraZeneca
Conditions:
HRRm mCRPC
Eligibility:
All Genders
Brief Summary
Study design: This study is local, multi-center, prospective, cohort study to collect real world data related mCRPC patients, prevalence of HRRm and to assess possible influence of HRRm on treatment ...
Eligibility Criteria
Inclusion
- Male 18 years age or older
- Provision of written informed consent
- Histologically confirmed diagnosis of prostate cancer
- Documented evidence of metastatic castration resistant prostate cancer (mCRPC)
- Patients who are on the first line therapy or already received one line of therapy due to mCRPC previously
- Availability of archival FFPE tissue from primary prostate tumor
- Availability of medical history (e.g. out-patient medical records or disease histories for hospitalized patients)
Exclusion
- • Patients participating in clinical studies
Key Trial Info
Start Date :
October 23 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2022
Estimated Enrollment :
331 Patients enrolled
Trial Details
Trial ID
NCT04712890
Start Date
October 23 2020
End Date
September 30 2022
Last Update
September 28 2023
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Barnaul, Altayskiy Kray, Russia
2
Research Site
Ufa, Bashkortostan Republic, Russia
3
Research Site
Chelyabinsk, Chelyabinsk Oblast, Russia
4
Research Site
Krasnoyarsk, Krasnoyarsk Krai, Russia